REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai > Cyclopeptides > 9 To 11 Peptide Repeating Units In Known Peptide Chain 9 To 11 Peptide Repeating Units In Known Peptide Chain9 To 11 Peptide Repeating Units In Known Peptide Chain patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/25/07 - 20070021346 - Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The described compounds include chemically modified peptides that not ... 01/18/07 - 20070015714 - Methods for treating fsh related conditions with gnrh antagonists Methods for treating FSH related conditions, such as prostatic intraepithelial neoplasia, pedophilia, infertility, or vaginal bleeding, with GnRH antagonists are disclosed. The methods of the invention generally feature administering to a subject a GnRH antagonist suitable for in vivo administration and able to reduce both plasma FSH and LH levels ... 01/18/07 - 20070015713 - Methods for treating prostate cancer Methods are provided for treating prostate cancer, preventing or slowing proliferation of cells of prostate origin, preventing prostate cancer in a patient at risk of contracting prostate cancer, preventing or inhibiting an upregulation of the cell cycle in prostate-derived cells in a patient, and decreasing the level of prostate-specific antigen ... 01/11/07 - 20070010451 - Method of protecting cells against damage and pharmaceutical composition comprising leumorphin The present invention relates to a method of protecting cells against damage caused at least in part by apoptosis, comprising administering to subjects a therapeutic dose of leumorphin having cytoprotective activity, and a pharmaceutical composition comprising an effective amount of leumorphin having a cytoprotective activity. ... 12/28/06 - 20060293244 - Anti-inflammatory compounds and uses thereof The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-κB-dependent target gene expression in a cell. ... 12/28/06 - 20060293243 - Stable, buffered, pharmaceutical compositions including motilin-like peptides Stable, pharmaceutical compositions including a synthetic motilin-like peptide in a buffered solution are disclosed. The composition provides for a peptide that remains stable and substantially retains its initial potency during extended storage and after steam sterilization. ... 12/21/06 - 20060287245 - Anti-tumor agents A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in ... 12/21/06 - 20060287244 - L-threonine derivatives of high therapeutic index The present invention is directed to a derivative comprised of an L-Threonine bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. The derivative has the same utility as the drug from which it is made, but it has enhanced therapeutic properties. In fact, the ... 12/21/06 - 20060287243 - Stable pharmaceutical compositions including motilin-like peptides Stable, pharmaceutical compositions including a synthetic motilin-like peptide in a buffered aqueous solution or in an unbuffered aqueous solution are disclosed. The composition provides for a peptide that remains stable and substantially retains its initial potency during extended storage and after steam sterilization. ... 12/21/06 - 20060287242 - Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only ... 12/21/06 - 20060287241 - Combination comprising n-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4-oxadiazol-2-y1]pyridine-3-sulphonamide and an lhrh analogue and/or bisphosphonate A combination, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, and an LHRH analogue and/or a bisphosphonate is described. ... 12/14/06 - 20060281685 - Methods of treatment using novel lhrh antagonists having improved solubility properties The invention relates to peptides which contain N-methylated amino acid units and have improved water solubility. The invention also relates methods for treating a hormone-dependent tumor or a non-malignant indication that is treatable by LH-RH suppression, the method comprising administering to a patient in need of the treatment a therapeutically ... 12/14/06 - 20060281684 - Polymyxin b analogs for lps detoxification The invention relates to SAEP II peptide dimers that mimic polymyxin B i.a. in its ability to bind non-covalently the lipopolysaccharide (LPS) of Gram-negative bacteria with high affinity, and therefore to detoxify LPS as polymyxin B does. The dimeric structure is maintained by a pair of disulphide bonds involving the ... 11/30/06 - 20060270605 - Compositions and methods for inhibiting cell growth and modulating gene expression The invention provides a method of inhibiting cancerous cell growth comprising contacting a collection of cancerous cells with a cell growth-inhibiting effective amount of a purified or isolated polypeptide comprising SE ID NO: 6 or variant thereof. The variant of SEQ ID NO: 6 comprises one, two, or three conservative ... 11/16/06 - 20060258595 - Polypeptide for the treatment of cancer and a method for preparation thereof This invention characterizes the specific peptide fragment derived from specially prepared zinc charged fetuin and a method of preparation thereof, wherein the fragment was found to contain an apoptosis-inducing activity. Specifically, the amino acid sequence of this peptide is His Ala Phe Ser Pro Val Ala Ser Val Glu. The ... 11/02/06 - 20060247177 - Gonadotropin releasing hormone analogues conjugates with steroid hormones A compound comprising a gonadotrophin releasing hormone analogue conjugated to a hormone moiety, or a derivative thereof, which is able to bind to a plasma hormone binding protein. The compounds may be used to treat hormone-dependent disorders such as cancer, or as a contraceptive. ... 10/26/06 - 20060241052 - Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer The present invention discloses compositions of facially amphiphilic polymers and oligomers and their use in methods for treating or reducing cancers in humans or animals. ... 10/26/06 - 20060241051 - Metastin derivatives and use thereof The present invention provides a metastin derivative in which the amino acids comprising metastin were modified by alternative chemical substituents resulting in metastin derivitives, having excellent blood stability and exhibiting cancer metastasis inhibiting action or cancer growth inhibiting action. ... 10/19/06 - 20060234941 - Peptide epitopes of vegfr-2/kdr that inhibit angiogenesis The disclosure provides antigenic peptides of Vascular Endothelial Growth Factor Receptor 2(VEGFR-2)/KDR. Pharmaceutical compositions including the peptides and/or antigen presenting cells that exhibit the VEGFR-2/KDR peptides on their cell surface are also provided. Methods for eliciting an immune response and for inhibiting angiogenesis by administering such pharmaceutical compositions are provided. ... 10/12/06 - 20060229251 - Treatment of t cell disorders The present invention relates to a method for treating a T cell disorder in a subject involving disrupting sex steroid signaling to the thymus and introducing into the subject bone marrow or haemopoietic stem cells (HSC). ... 09/28/06 - 20060217315 - Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method The present invention relates to a method of controlled ovarian hyperstimulation in a mammalian female, said method comprising administration to said female of a substance having follicle stimulating hormone activity (FSH substance) in an amount effective to stimulate follicular development and of anti-P in an effective amount to prevent a ... 09/21/06 - 20060211625 - New hybrid oligomers, their preparation process and pharmaceutical compositions containing them The present invention relates to compositions and methods for producing therapeutic oligomeric compounds. In one aspect the invention relates to methods for administering the oligomeric compounds for the treatment and prevention of disease, for example, a fungal infection, bacterial infection, or cancer, in a mammal. In particular, the invention relates ... 09/21/06 - 20060211624 - Methods and compositions for the treatment of parkinson's disease and other alpha-synucleinopathies The present invention provides novel methods for the treatment of Parkinson's disease and other α-synucleinopathies. The methods of the invention include treatment with inhibitors of transglutaminase, which can inhibit aggregation of α-synuclein. Also provided are screening assays for novel inhibitors of transglutaminase which may be used in the treatment of ... 09/14/06 - 20060205667 - Wt1 substitution pepides Novel substituted type peptides of WT1 wherein the cysteine residue is substituted with a defined amino acid residue, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. Peptides which comprise an amino acid sequence of the formula: X—Y-Thr-Trp-Asn-Gln-Met-Asn-Leu ... 09/07/06 - 20060199768 - Inhibitors of reca activities for control of antibiotic-resistant bacterial pathogens Compounds for modulating RecA protein activity are provided. In some embodiments, the compounds modulate RecA activity by interfering with assembly of monomeric RecA protein subunits into a nucleoprotein filament. In some embodiments, the compounds modulate RecA activity by interfering with adenosine triphosphate hydrolysis by the RecA protein. Methods of screening ... 08/31/06 - 20060194737 - Hepta-, octa-and nonapeptides having antiangiogenic activity Compounds of formula (SEQ ID NO:1), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis. ... 08/31/06 - 20060194736 - Polypeptide for the treatment of cancer and a method for preparation thereof This invention characterizes the specific peptide fragment derived from specially prepared zinc charged fetuin and a method of preparation thereof, wherein the fragment was found to contain an apoptosis-inducing activity. Specifically, the amino acid sequence of this peptide is His Thr Phe Ser Gly Val Ala Ser Val Glu. The ... 08/24/06 - 20060189540 - Peptides for diagnostic and therapeutic methods for celiac sprue Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. Analogs of such oligopeptides are useful in the inhibition of immune responses. ... 08/24/06 - 20060189539 - Novel gnrh analogues with antitumour effects and pharmaceutical compositions thereof The present invention provides peptides and pharmacologically active compounds including gonadotropin-releasing hormone (GnRH) analogues according to formulas of the invention, wherein the compounds show an antitumour effect. The invention additionally provides compositions including these peptides and compounds. ... 08/24/06 - 20060189538 - Peptides and nucleic acids of the cathelicidin family, derived from fish, and uses thereof The invention relates to anti-microbial and immunostimulatory molecules of the cathelicidin family derived from fish. The invention provides a novel cathelicidin molecule, fragments, derivatives and uses thereof, and nucleic acids encoding the same. ... 08/10/06 - 20060178311 - Control of lactation The present invention provides three novel peptides identified from cow's milk and further to compositions and methods containing the same for use in the modulation of the milk secretion rate of a lactating cell. Specifically, at least one of the peptides provided by the invention can be used to control ... 07/27/06 - 20060166891 - Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia The present invention provides compositions adapted to enhance reverse cholesterol transport in mammals. The compositions are suitable for oral delivery and useful in the treatment and/or prevention of hypercholesterolemia, atherosclerosis and associated cardiovascular diseases. ... 07/27/06 - 20060166890 - Non-t cell binding peptides and their uses The present invention provides a non-T cell binding peptide and its analogs used for the treatment of rheumatoid arthritis. The polypeptide therapeutic agent can specifically inhibit abnormal immune responses of the rheumatoid arthritis, and fundamentally control the progression of this disease with effect on the initiating factor of the disease ... 07/20/06 - 20060160745 - Agents for preventing postoperative recurrence of premenopausal breast cancer The agent for preventing the postoperative recurrence of premenopausal breast cancer comprising a GnRH agonist or antagonist of the present invention can prevent the postoperative recurrence of premenopausal breast cancer without severe side effects. In addition, by using the agent of the present invention in the form of a long ... 07/20/06 - 20060160744 - Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder The invention concerns the use of a bombesin/gastrin releasing peptide antagonist in the treatment of inflammatory and immune-mediated inflammatory conditions, in particular sepsis, acute lung injury and rheumatoid arthritis as well as for the treatment or prophylaxis of brain disorders, preferably bipolar disorder, and in particular the different forms and/or ... 07/20/06 - 20060160743 - Peptides that selectively home to heart vasculature and related conjugates and methods The present invention provides a variety of isolated peptides and peptidomimetics, which can be useful, for example, in constructing the conjugates of the invention or, where the peptide itself has biological activity, in unconjugated form as a therapeutic for treating any of a variety of cardiovascular diseases as described below. ... 06/29/06 - 20060142202 - Compositions and methods for targeted delivery of immune response modifiers The present invention provides immunomodulatory compositions include an immune response modifier moiety coupled to a targeting moiety. In another aspect, the invention provides methods of providing targeted delivery of an IRM, generating a localized immune response, and treating a condition in a subject. Generally, the methods include administering to the ... 06/22/06 - 20060135435 - Agent that retards transformation of hormone-dependent cancer to non-hormone-dependent cancer The present invention relates to a composition that retards the transformation of a hormone-dependent cancer to a non-hormone-dependent cancer, which contains a hormonal agent. The composition of the present invention that retards the transformation of a hormone-dependent cancer to a non-hormone-dependent cancer, which contains a hormonal agent, is capable of ... 06/22/06 - 20060135434 - New peptides The present invention relates to new peptides for targeting to vascular endothelial growth factor receptor 2, VEGFR-2. The invention further relates to their use in therapeutically effective treatment as well as for diagnostic imaging techniques. ... 06/22/06 - 20060135433 - Phenolic binding peptides The present application relates to peptides which bind to tannin, polyphenolic or anthocyanin compounds, and particularly to tea and wine stains on a fabric or other surface. The invention also concerns binding peptide conjugates which includes a binding peptide coupled to an agent and the use of the binding peptide ... 06/22/06 - 20060135432 - Agonists and antagonists of conadotropin-releasing hormone-2, and use thereof The present invention relates to agonists and antagonists of gonadotropin-releasing hormone-2 (GnRH-2), which regulates the activity of GnRH-2 by specifically binding to GnRH-2 receptors, and uses thereof The pharmaceutical compositions comprising the GnRH-2 agonists and antagonists according to the present invention are useful for the treatment of reproductive physiology diseases ... 06/15/06 - 20060128629 - Partial peptide mimetics and methods Partial peptide mimetics and methods of making and using, wherein the partial peptide mimetics have a first amino acid sequence comprising ANIKLSVQMKL (SEQ ID NO:8), a homolog thereof, or a segment of SEQ ID NO:8 or a homolog thereof, a second amino acid sequence comprising IIVKLND (SEQ ID NO:2), a ... 06/15/06 - 20060128628 - Human tissue antigen-binding peptides and their amino acid sequences The invention relates to a peptide that has epitopes with amino acid sequences selected from the S protein of SARS virus. Such peptides can bind human tissue antigen to form a complex, and can induce cytotoxicity. The invention relates further to a vaccine or diagnostic agent formed by combining said ... 05/18/06 - 20060105958 - Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using a pheromone, a luteinizing hormone (LH) and/or a human chorionic gonadotrophin (hCG). The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons ... 05/18/06 - 20060105957 - Loop peptide and tgfalpha for stimulating stem cell proliferation and migration There is disclosed a novel genus of small peptides, much smaller than human TGFα, was discovered as having TGFα biological activity and therefore are useful as pharmacologic agents for the same indications as full length TGFα polypeptide. There is further disclosed that TGFα and consequently the genus of small peptides ... 05/11/06 - 20060100155 - Method for the therapeutic management of endometriosis The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to 12 weeks. According to another aspect of the present invention, the short term LH-RH treatment is ... 05/11/06 - 20060100154 - Long-acting gonadotropin-releasing hormone analogs and methods of use thereof The present invention relates to the design, synthesis and biological evaluation of potent long-acting gonadotropin-releasing hormone (GnRH) analogs including agonists and antagonists comprising a GnRH peptide conjugated to emodic acid or an emodic acid derivative. These long acting analogs bind to GnRH receptors with high affinity and are devoid of ... 05/04/06 - 20060094662 - Pharmaceutical compositions for sustained drug delivery Sustained delivery formulations comprising a water-insoluble complex of a peptide and a plurality of ligands are disclosed. The formulations of the invention allow for loading of high concentrations of peptide in a small volume and for delivery of a pharmaceutically active peptide for prolonged periods, e.g., one month, after administration ... 05/04/06 - 20060094661 - Ny-eso-1 peptide analogs Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which ... 05/04/06 - 20060094660 - Inhibitor of the shh signalling patway and a testosterone supressing agent for the treatment of cancer A method of protecting a patient from possible adverse effects of a treatment involving inhibition of the SHH-signalling pathway in the patient, the method comprising suppressing testosterone or its effect in the patient. A method of treating a proliferative disease such as cancer in a patient the method comprising inhibiting ... 04/27/06 - 20060089309 - Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds The present invention provides for a method for stimulating the proliferation of pluripotential stem cells in a mammal comprising administration of pregnancy related compounds more particularly human chorionic gonadotropin, leutenizing hormone or prolactin. The present invention further provides for a method of treatment of tissues or organs experiencing cellular damage, ... 04/27/06 - 20060089308 - Method of improving ovulation induction using an androgen such as dehydroepiandrosterone A method of preconditioning ovulation induction in a human female comprises of administering an androgen, for example, DHEA, for at least about four consecutive months. DHEA may be administered along with high dose gonadotrophins in ovulation induction treatments. Moreover, DHEA may be administered with follicle stimulating hormone, human menopausal gonadotrophin, ... 04/27/06 - 20060089307 - Peptides that bind to the heparin binding domian of vegf and vegfr-2 The present invention relates to new peptides for targeting that bind to the heparin binding domain of vascular endothelial growth factor and its receptor vascular endothelial growth factor receptor 2, VEGFR-2. The invention further relates to their use in therapeutically effective treatment as well as for diagnostic imaging techniques. ... 04/20/06 - 20060084609 - Synthetic hla binding wt-1 peptide analogues and uses thereof The present invention is directed to a synthetic peptide comprising a sequence of amino acids containing at least a segment that is an analogue of a native peptide that specifically binds to HLA A0201 or HLA A0301 molecules on a cell characteristic of a pathophysiologic state in a mammal. The ... 04/13/06 - 20060079460 - Purified lh Recombinant human luteinizing hormone (LH) having a specific bioactivity of from 20,522 to 31,229 IU/mg and obtainable from a process for the purification of recombinant LH from a sample of crude recombinant LH in the supernatant of CHO cells which comprises the combined use of ion-exchange chromatography and reverse phase ... 04/06/06 - 20060074027 - Sustained-release preparations A sustained release preparation comprising a combination of a microcapsule which gradually releases a GnRH agonist or a salt thereof for a long term, and a microcapsule which gradually releases a GnRH agonist or a salt thereof for a short term. ... 03/30/06 - 20060069032 - Beta-endorphin activity in cosmetics and dermatology The subject of the invention is the use of at least one compound chosen from β-endorphin and β-endorphin-mimetic agents on the keratinocytes of the skin, for example in a cosmetic composition to enhance the barrier function of the skin, enhance its resistance to stress and in particular to pollution. It ... 03/30/06 - 20060069031 - Use of gnrh agonists to support the luteal phase during infertility treatment The present invention concerns the use of an agonist of an hypothalamic hormone for the preparation of a pharmaceutical agent to support the luteal phase during infertility treatment of female mammals and more specifically of women. According to this invention, the pharmaceutical agent is suitable to be used for supporting ... 03/16/06 - 20060058241 - Methods of treating disorders having a component of mercury toxicity The present invention relates to methods of lowering the level of mercury in a subject, methods of lowering the level of mercury in a child diagnosed with autism and methods of assessing the risk of whether a child is susceptible of developing autism. ... 03/09/06 - 20060052307 - Bone growth factor X2, X3, X6 and X7 are non polar neutral amino acids or uncharged polar amino acids; Z represents a blocking group; and n is an integer from 1 to 3. ... 02/23/06 - 20060040868 - Methods for treating premature infants Methods of treating premature infants include administering, to an infant, an agent that increases the blood or tissue levels, production, function, or activity of hCG, LH, FSH, GnRH, or activin or that decreases the blood or tissue levels, production, function, or activity of follistatin and inhibin. ... 02/23/06 - 20060040867 - Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections A novel method of treating and preventing viral infection is provided. In particular a method of blocking viral infection facilitated by a serine proteolytic (SP) activity is disclosed, which consists of administering to a subject suffering or about to suffer from viral infection a therapeutically effective amount of a compound ... 02/16/06 - 20060035837 - Compounds that inhibit hsp90 protein-protein interactions with iap proteins Disclosed herein are compounds that inhibit Hsp90 interactions with IAP proteins, such as Survivin, XIAP, cIAP1, or cIAP2, and methods for identifying and using such compounds. ... 02/09/06 - 20060030532 - Novel antimicrobial compounds The invention features an antimicrobial composition comprising a substance P peptide and methods of inhibiting growth of a microorganism by contacting the microorganism with a substance P peptide. Bacterial and fungal pathogens are inhibited by the substance P compositions. ... 01/26/06 - 20060019903 - Compositions and methods for treating precocious puberty The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and ... 01/19/06 - 20060014693 - Peptide inhibiting platelet derived growth factor (pdgf-bb) and fibroblast growth factor (bfgf) activity A novel peptide, derived from the human fibroblast growth factor (bFGF), is identified. Said molecule is able to inhibit in vitro the effects of Platelet Derived Growth Factor (PDGF-BB) and basic Fibroblast Growth Factor (bFGF) on primary rat smooth muscle cells (RASMC) and primary bovine endothelial cells (BAEC). Said molecule ... 01/12/06 - 20060009392 - Antineoplastic peptides wherein R1, R2, X, A, B, D, E, G, K, and s have the meanings stated in the description. The compounds have antineoplastic activity. ... 01/05/06 - 20060003941 - Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity The invention provides compounds having immune-modulating and/or anti-inflammatory and/or anti-viral activity, wherein compounds of the invention include peptides and peptidomimetics. The invention further provides methods of using immune-modulating and/or anti-inflammatory and/or anti-viral compounds of the invention. In particular, the invention provides methods for treating a disease related to an immune ... 12/15/05 - 20050277594 - Polypeptide for the treatment of cancer and a method for preparation thereof This invention characterizes the specific peptide fragment derived from specially prepared zinc charged fetuin and a method of preparation thereof, wherein the fragment was found to contain an apoptosis-inducing activity. Specifically, the amino acid sequence of this peptide is His Thr Phe Ser Gly Val Ala Ser Val Glu and ... 11/17/05 - 20050256056 - Peptide inhibitors of hiv Provided are peptides, peptide analogs, and peptide mimetics that inhibit HIV activity, pharmaceutical compositions comprising such peptides and peptide analogs, and methods of inhibiting HIV activity and/or transmission by administering the peptides and peptide analogs to a subject. ... 11/17/05 - 20050256055 - Compounds and methods for reducing undesired toxicity of chemotherapeutic agents Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium. ... 11/17/05 - 20050256054 - Drug therapy for celiac sprue Celiac Sprue and/or dermatitis herpetiformis arc treated by interfering with HLA binding of immunogenic gluten peptides. The antigenicity of gluten oligopeptides and the ill effects caused by an immune response thereto are decreased by administration of an HLA-binding peptide inhibitor. Such inhibitors are analogs of immunogenic gluten peptides and (i) ... 11/10/05 - 20050250700 - Kdr and vegf/kdr binding peptides The present invention provides, inter alia, peptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR ... 11/03/05 - 20050245455 - Gonadotropin releasing hormone antagonists in gel-forming concentrations Pharmaceutical compositions are provided for the treatment of steroid-dependent and other diseases. The compositions are solutions for subcutaneous or intramuscular injection, and the active agent is a GnRH antagonist peptide according to general formula (1): Ac-DNal-DCpa-DPal-Ser-Aph(X1)-DAph(X2)-Leu-Lys(iPr)-Pro-DAla-NH2 present at a concentration sufficient to from a gel following administration. ... 10/20/05 - 20050233970 - Methods for treating long qt syndrome The present invention provides compositions and methods for treating QT prolongation in a subject in need thereof. The method comprises the step of administering to the subject a therapeutically effective amount of an agent which increases the androgen level of the subject. ... 10/06/05 - 20050222040 - Vertebrate peptide modulators of lipid metabolism The invention provides vertebrate lipid mobilizing peptides, derivative compounds and compositions as well as methods of using such peptides, derivative compounds and compositions for modulating the lipid metabolism of a vertebrate subject. ... 10/06/05 - 20050222039 - Animal treatment A method for affecting a physiological response of an animal to circulating level of prolactin and/or prolactin mimetics, characterised by the step of a) modulating prolactin receptors. ... 09/22/05 - 20050209160 - Protein kinase c peptides for use in withdrawal A method for managing withdrawal from an addictive substance is described. The method involves administering one or more peptides having specific activity for the ε and/or γ isozyme of protein kinase C (PKC). The peptide(s) can be administered prior to, concurrent with, or subsequent to administration of the addictive substance. ... 08/11/05 - 20050176644 - Compounds and compositions for prevention of overdose of oxycodone The invention relates to pharmaceutical compounds and compositions comprised of a chemical moiety attached to an opioid such as oxycodone in a manner that substantially decreases the potential of the opioid to cause overdose. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of ... 07/28/05 - 20050164948 - Methods of treatment with prosaposin-derived peptides The invention provides a method of alleviating neuropathic pain in a subject by administering a neuropathic pain alleviating amount of prosaposin receptor agonist to the subject. The invention also provides a method of inhibiting the onset of neuropathic pain in a subject by administering neuropathic pain alleviating amount of prosaposin ... 07/28/05 - 20050164947 - Protein kinase c peptides for use in withdrawal A method for managing withdrawal from an addictive substance is described. The method involves administering one or more peptides having specific activity for the ε and/or γ isozyme of protein kinase C (PKC). The peptide(s) can be administered prior to, concurrent with, or subsequent to administration of the addictive substance. ... 07/28/05 - 20050164946 - Canine ghrh gene, polypeptides and methods of use The present invention relates to a canine pre-proGHRH polypeptide, a canine mature GHRH peptide, an isolated polynucleotide which encodes the canine pre-proGHRH or the canine mature GHRH. The invention also encompasses vectors encoding and expressing the canine pre-proGHRH or the canine GHRH which can be used to treat disease and ... 07/14/05 - 20050153898 - Peptides for the treatment of alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders A pharmaceutical composition comprising peptide A-13 Arg-Gln-Val-Phe-Gln-Val-Ala-Tyr-Ile-Ile-Ile-Lys-Ala (SEQ ID NO:3). ... 07/14/05 - 20050153897 - Peptides for the treatment of alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders Val-Arg-Trp-Gly. ... 07/14/05 - 20050153896 - Peptides for the treatment of alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders Leu-Val-Phe-Met. ... 07/14/05 - 20050153895 - Peptides for the treatment of alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders A pharmaceutical composition comprising peptide AG73 Arg-Lys-Arg-Leu-Gln-Val-Gln-Leu-Ser-Ile-Arg-Thr (SEQ ID NO:1). ... 07/14/05 - 20050153894 - P21 peptides The present invention relates to p21 derived peptides capable of inhibiting CDK/cyclin complexes, particularly cyclins A or E/CDK2, by modifying the interaction with their substrates. The peptides are derived from a C-terminal region of p21 and display selectivity for cyclin/CDK2 inhibition over cyclin/CDK4 inhibition. Variants of such peptides particularly involving ... 06/30/05 - 20050143311 - Peptide having cytotoxicity inhibitory activity and method of screening these peptide having cytotoxicity inhibitory activity A peptide fragment or a series of peptide fragments containing one or more selenocysteine that has a lowered toxicity than selenocystine and that exhibits a cytotoxicity-inhibitory activity. The peptide fragment or a series of peptide fragments according to the present invention has preferably the amino acid sequence from 260th to ... 06/16/05 - 20050130900 - Sustained release drug formulations containing a carrier peptide The invention features a method of administering one or more therapeutic agents to a patient and delivering said agent or agents continuously over an extended period of time, said method comprising: obtaining a pharmaceutical composition including a peptide carrier, one or more therapeutic agents, and up to 30 percent, by ... 06/16/05 - 20050130899 - Tumor antigens Tumor antigen peptides that induce CTL from peripheral blood mononuclear cells of a patient with prostate cancer in an HLA-A2-restricted or an HLA-A24-restricted manner were identified based on the amino acid sequences of PSA, PSM, and PSCA, which are proteins known as markers of prostate cancer. Also disclosed is a ... 06/09/05 - 20050124548 - Peptide antiangiogenic drugs wherein A0 is selected from hydrogen or an acyl group; A10 is a hydroxyl group or an amino acid amide; and A1, A2, A3, A4, A5, A6, A7, A8, and A9 are amino acyl residues as defined herein. ... 06/09/05 - 20050124547 - Tau-conotoxin peptides The invention relates to relatively short peptides (termed τ-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. ... ### FreshPatents.com Support |